Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

682 results about "Hepatic disorders" patented technology

Liver disease is varied and there are many conditions that affect this vital organ, including cirrhosis, alcoholic fatty liver, and hepatitis. Primary sclerosing cholangitis is a type of inflammatory liver disease affecting the bile ducts. Hepatocellular carcinoma is a type of liver cancer that is among the most serious of liver diseases.

Application of DRAM1 as diagnosis and treatment target for resisting non-alcoholic fatty liver disease related hepatocellular carcinoma in preparation of kit, carrier and medicine

The invention belongs to the technical field of biological medicines, and provides application of DRAM1 as a diagnosis and treatment target for resisting non-alcoholic fatty liver disease related hepatocellular carcinoma in preparation of a kit, a carrier and a medicine aiming at the problem of lack of effective treatment targets of NAFLD-related HCC. As a target spot for resisting the non-alcoholic fatty liver disease related hepatocellular carcinoma, the expression level of the DRAM1 in liver tissues of non-alcoholic fatty liver disease related hepatocellular carcinoma patients and mice is increased. According to the application disclosed by the invention, research is developed aiming at the effect of the DRAM1 in the generation and development of NAFLD-related HCC, the analysis of TCGA liver cancer queue data and a GSE164760 data set is taken as an entry point, the influence of the DRAM1 on the diagnosis and prognosis of the liver cancer is comprehensively analyzed, and verification is carried out through a mouse in-vivo experiment, so that a new thought and a new target spot are provided for clinical diagnosis and treatment of the liver cancer.
Owner:OCEAN UNIV OF CHINA +1

Application of hispidulin in preparation of lipid de novo synthesis inhibitor or metabolism-related fatty liver disease treatment or prevention product

The invention relates to the field of biological medicine, in particular to application of hispidulin in preparation of a lipid de novo synthesis inhibitor or a metabolism-related fatty liver disease treatment or prevention product. The hispidulin disclosed by the invention has a chemical structure as shown in a formula (I). The hispidulin in the invention reverses liver cell lipid droplet excessive infiltration induced by high-dose fructose in a dose-dependent manner; furthermore, the hispidulin dose-dependent ameliorating obesity signs in HFD-induced MAFLD model mice, including liver weight, body weight, blood lipid level, liver fat content, and insulin resistance, without significantly reducing food intake.
Owner:SHANGHAI SEVENTH PEOPLES HOSPITAL

Molecular marker methylation level detection reagent for primary hepatocellular carcinoma and its application

The present invention discloses the application of a molecular marker methylation level detection reagent for primary hepatocellular carcinoma in the preparation of a detection reagent product, and belongs to the field of gene detection technology. By screening the methylation level of the CpG site in the detected region and its reverse complementary sequence, it is identified whether the target sample is from a primary hepatocellular carcinoma patient. The methylation level of the CpG site in the above region has good sensitivity and specificity for the screening or auxiliary diagnosis of primary hepatocellular carcinoma, and can be used to distinguish samples from patients with primary hepatocellular carcinoma, samples from patients with benign liver diseases (cirrhosis, hepatitis, etc.) and samples from healthy people. The detection reagent and application of the methylation level of the molecular marker can improve the detection rate of early primary hepatocellular carcinoma.
Owner:BEIJING LAIMENG JUNTAI INTL MEDICAL TCHNLGY DVLPMNT CO LTD +1

Composition, traditional Chinese medicine, preparation method of traditional Chinese medicine and application of traditional Chinese medicine in hepatitis

The invention belongs to the field of traditional Chinese medicine preparations, and particularly relates to a composition, a traditional Chinese medicine, a preparation method thereof and application in hepatitis. The traditional Chinese medicine composition is composed of capillary artemisia, cape jasmine, wine-treated rhubarb, radix bupleuri, schisandra chinensis, radix curcumae, turmeric, rhizoma alismatis, herba lycopi and fortune eupatorium herb, and has the effects of clearing Yang and clearing damp-heat, benefiting dampness of tri-jiao and regulating qi and blood together, and clinical curative effect feedback and animal experiments prove that the curative effect of the traditional Chinese medicine composition can be used for treating non-alcoholic steatohepatitis in a mouse model. The content of AST and ALT in mouse serum is reduced, the level of inflammatory factors IL-1beta and TNF-alpha is reduced, and the level of an anti-inflammatory factor IL-10 is improved. Furthermore, the traditional Chinese medicine for removing heat from the liver and reducing lipid significantly reduces the levels of TG, TC and FFA in liver tissue, pathology shows that the traditional Chinese medicine can significantly relieve hepatic cell fatty degeneration, inflammatory reaction cell infiltration and other pathological symptoms, and a new thought is brought to treatment of the non-alcoholic fatty liver disease through the traditional Chinese medicine.
Owner:BEIJING UNIV OF CHINESE MEDICINE

Use of benzethonium chloride in preparing medicine for improving or treating non-alcoholic fatty liver disease

The present invention relates to a use of benzethonium chloride in preparing a drug for improving or treating non-alcoholic fatty liver disease, and relates to the technical field of new uses of products. The present invention discovers for the first time a new use of benzethonium chloride for improving or treating non-alcoholic fatty liver disease. Benzethonium chloride can reduce hepatocyte lipid deposition and regulate hepatocyte lipid metabolism disorder by intervening in a cell lipid deposition model; it can improve liver lipid accumulation in mice caused by lipid metabolism disorder by administering through the digestive tract, and can improve liver coefficient, liver function, hepatic lobular inflammation, and liver fibrosis. The benzethonium chloride of the present invention can be used for the preparation of drugs for improving or treating non-alcoholic fatty liver disease. The benzethonium chloride of the present invention can inhibit the expression of human apolipoprotein C3, thereby reducing the generation of lipids, and is applied to drugs for treating non-alcoholic fatty liver disease, opening up a new use of benzethonium chloride and providing a new drug option for treating non-alcoholic fatty liver disease.
Owner:CHANGCHUN NORMAL UNIV

Methods of treating Cushing's syndrome and liver disease and reducing hepatotoxicity of other drugs administered by patients

PendingCN119317433AOrganic active ingredientsAntipyreticLiver enzyme levelsItraconazole
Disclosed are methods and uses for treating a subject having a condition selected from liver disease, Cushing's syndrome or Cushing's disease, cancer, infection, inflammation, cardiovascular, endocrine or kidney disease, and combinations thereof, or other disease that may thus be administered a drug that may cause hepatotoxicity, the methods and uses having no adverse effects on the liver. The liver diseases comprise fatty liver diseases, high-level liver enzyme can be effectively reduced, and good safety is achieved. The methods and uses include administering to a subject an effective amount of a selective non-steroidal glucocorticoid receptor modulator, such as relacan, including methods and uses for use in combination with other drugs, without adversely affecting liver enzyme levels or liver function. In embodiments, another drug may be a drug that may cause hepatotoxicity, such as a drug that inhibits the CYP3A enzyme, such as itraconazole or ketoconazole.
Owner:CORCEPT THERAPEUTICS INC

Reagent and kit for detecting methylation level of molecular marker and application of reagent and kit

The invention discloses a reagent and a kit for detecting methylation level of a molecular marker and application of the reagent and the kit, and belongs to the technical field of gene detection. By detecting the methylation level of the CpG site in the chr2: 63053864-63054353 region (taking an hg38 genome as a reference genome), whether a target is a primary hepatocellular carcinoma patient or not can be identified. The detection area shows a high methylation level for patients with primary hepatocellular carcinoma, and the detection area shows a low methylation level for patients with liver diseases and healthy people. Detection of the methylation level of the CpG loci in the region has good sensitivity and specificity for screening and auxiliary diagnosis of the primary hepatocellular carcinoma, and can be used for distinguishing samples of patients with the primary hepatocellular carcinoma from samples of patients with liver benign diseases (liver cirrhosis, hepatitis and the like) and samples of healthy people.
Owner:GUANGZHOU YOUZE BIOLOGICAL PHARM TECH CO LTD +1

Application of Osge as molecular target in preparation of medicine for preventing and / or treating fatty liver

The invention discloses application of Osge as a molecular target to preparation of a medicine for preventing and / or treating fatty liver. According to the invention, the key effect of Osge as a therapeutic target in the treatment of fatty liver diseases caused by high fat diet is confirmed for the first time and is verified in a mouse model, and a method of overexpressing Osge through virus transfection proves that lipid deposition in liver tissues can be effectively reduced and liver balloon-like degeneration can be relieved by improving the expression level of Osge in the liver, so that the fatty liver diseases caused by high fat diet can be effectively treated. The accumulation of lipid droplets is reduced. The invention shows that Osge can be used as a new molecular target for preventing and treating fatty liver, and has important clinical application value in the aspect of treating metabolism-related fatty liver diseases.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Application of siRNA composition in preparation of medicine for treating liver diseases and medicine

The invention discloses application of a siRNA composition in preparation of a medicine for treating liver diseases and the medicine. The siRNA composition at least comprises PCBP2-siRNA and PD-L1-siRNA. The invention discovers that PCBP2-siRNA and PD-L1-siRNA can effectively reduce type I collagen deposition in a mouse hepatic fibrosis model induced by CCL4 for the first time. The result shows that the two siRNAs both have a potential anti-fibrosis effect. And when the PCBP2-siRNA and the PD-L1-siRNA are used in a combined manner, the inhibition effect of the PCBP2-siRNA and the PD-L1-siRNA on the type I collagen deposition is more obvious than that of the PCBP2-siRNA which is independently used with any siRNA. The result shows that the liver fibrosis degree can be more effectively relieved through combined application of the two siRNAs.
Owner:HEBEI UNIV OF TECH

Application of selenium-rich polypeptide to inhibition of NLRP3 inflammasome-related inflammation and regulation of cholesterol transport protection lipid metabolism abnormality

ActiveCN120081950AAntibody mimetics/scaffoldsMetabolism disorderCholesterolCoronary atherosclerosis
The invention belongs to the field of active peptides, and particularly relates to application of selenium-rich polypeptide in inhibiting NLRP3 inflammasome-related inflammations and regulating cholesterol transport protection lipid metabolism abnormality, the selenium-rich polypeptide is prepared by chelating Adi-Apo fusion protein as shown in SEQ ID NO: 3 and sodium selenite (Na2SeO3); the selenium peptide chelate has the effects of remarkably reducing the concentration of TC / TG in serum, reducing the liver lipid deposition and inflammation level and reducing the atherosclerotic plaque area proportion through high oxidation resistance and high anti-inflammatory activity, and can be used for treating and / or preventing lipid metabolism disorder diseases such as metabolism-related fatty liver diseases and coronary atherosclerosis.
Owner:ANKANG CENT HOSPITAL

Molecular marker methylation level detection reagent for primary hepatocellular carcinoma and application of molecular marker methylation level detection reagent

The invention discloses application of a molecular marker methylation level detection reagent for primary hepatocellular carcinoma in preparation of a detection reagent product, and belongs to the technical field of gene detection. Whether a target sample is from a primary hepatocellular carcinoma patient or not is identified by screening out a detected area and the methylation level of a CpG site in a reverse complementary sequence of the detected area. The methylation level of the CpG site in the region has good sensitivity and specificity for screening or auxiliary diagnosis of the primary hepatocellular carcinoma, and can be used for distinguishing a primary hepatocellular carcinoma patient sample, a benign liver disease (liver cirrhosis, hepatitis and the like) patient sample and a healthy person sample. The detection reagent for detecting the methylation level of the molecular marker and the application can improve the detection rate of early primary hepatocellular carcinoma.
Owner:BEIJING LAIMENG JUNTAI INTL MEDICAL TCHNLGY DVLPMNT CO LTD +1

Pharmaceutical composition of semaglutide and salt thereof for intranasal administration

Pharmaceutical compositions of semaglutide or salts thereof for intranasal administration for the treatment of diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) or neurodegenerative diseases. The method of delivering semaglutide through the intranasal route avoids repeated injections and improves systemic absorption of semaglutide as compared to oral pastilles.
Owner:PENTIDE THERAPEUTICS LTD

Therapeutic regimens and methods for reducing body weight in subjects with fatty liver disease using GLP-1R and GCGR agonists

The present disclosure relates to a once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same to induce weight loss in humans suffering from fatty liver disease, where the humans may or may not suffer from other complications, such as type 2 diabetes and / or cardiovascular disease / disorder. The dual agonist of the GLP-1R and the GCGR comprises a peptide product of SEQ ID NO. 1 (pemvidude), and a preparation method of the GLP-1R and GCGR dual agonist.
Owner:斯皮特弗尔制药有限责任公司

Microacidophilic oligotrophic monocytogenes capable of improving metabolic liver disease and its application

The present invention discloses Stenotrophomonas acidaminiphila and its application for improving metabolic liver disease, and belongs to the field of microbial technology. The deposit number of the above-mentioned Stenotrophomonas acidaminiphila is CGMCC No.26919. It has been verified through experiments that the bacteria have an inhibitory effect on the increase of plasma ALT and AST caused by alcohol; it has an inhibitory effect on the increase of MDA, and restores the activity of liver GSH and SOD; it has an inhibitory effect on the increase of inflammatory factors in liver cells; it reduces liver fat vesicles and reduces inflammatory cell infiltration. Therefore, the bacteria can effectively alleviate liver damage caused by alcohol. In addition, the bacteria can also effectively alleviate the symptoms of non-alcoholic fatty liver disease caused by high fat. Therefore, the present invention has important clinical significance for the relief and treatment of metabolic-related fatty liver disease including alcoholic liver disease and non-alcoholic fatty liver disease.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

Traditional Chinese medicine composition for treating liver depression and spleen deficiency syndrome metabolism-related fatty liver disease

The invention belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating liver depression and spleen deficiency syndrome metabolism-related fatty liver disease, which is prepared from the following raw materials in parts by weight: 8 to 10 parts of ginseng, 10 to 15 parts of radix bupleuri, 10 to 15 parts of radix curcumae, 6 to 9 parts of ginger processed pinellia, 6 to 10 parts of fructus amomi, 10 to 15 parts of rhizoma atractylodis, 10 to 15 parts of poria cocos, 10 to 15 parts of semen hoveniae, 10 to 15 parts of radix rehmanniae, 8 to 10 parts of rhizoma polygoni cuspidati and 6 to 9 parts of lignum dalbergiae odoriferae. The traditional Chinese medicine composition is used for treating the metabolism-related fatty liver diseases from the aspects of liver depression, spleen deficiency and phlegm-blood stasis, starts from the core pathological chain of liver depression, spleen deficiency, phlegm-dampness and blood stasis, has the functions of soothing the liver, tonifying the spleen, resolving dampness, reducing fat and promoting blood circulation to remove meridian obstruction, and is particularly suitable for patients with liver depression, spleen deficiency and metabolism-related fatty liver diseases. Clinical tests prove that the traditional Chinese medicine composition has a good treatment effect on patients with liver depression and spleen deficiency syndrome metabolism-related fatty liver diseases, the total effective rate reaches 94% or above, and the traditional Chinese medicine composition is mild in medicine property, good in safety, stable in curative effect, not prone to relapse and suitable for being taken for a long time.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Application of Prevotella copri as children metabolism-related fatty liver disease biomarker and therapeutic target

The invention discloses application of Prevotella copri as a children's metabolism-related fatty liver disease (MASLD) biomarker and a therapeutic target, relates to the fields of medical microbiology and metabonomics, and explores biological characteristics of the Prevotella copri and an action mechanism of the Prevotella copri in children's metabolism-related fatty liver disease (MASLD). The invention also analyzes the effect of Prevotella copri and its metabolite 5-aminovaleric acid in the development of children's metabolism-related fatty liver disease (MASLD), and provides a basis for developing a method for treating metabolism-related fatty liver disease (MASLD) based on intestinal microorganisms. According to the present invention, the Prevotella copri is subjected to intragastric administration to the mouse fed with the high fat diet, such that the liver fat change and the intestinal flora disorder aggravating are found; the metabolite 5-amino valeric acid of the Prevotella copri can be used for aggravating the adiposis of the liver cells. Therefore, the Prevotella copri and the metabolite 5-aminovaleric acid of the Prevotella copri can be used as a biomarker and a therapeutic target for diagnosis, treatment, prognosis evaluation or drug screening of the MASLD (Metabolism-related Fatty Liver Disease) of children.
Owner:SHANGHAI INST OF PEDIATRIC RES

Feed composition for construction of steatohepatitis animal model

The present invention relates to a composition for inducing liver disease in a mammal and a mammal with a liver disease induced using the same. The animal model of the present invention has been found to be an excellent animal model in which fatty liver, hepatic fibrosis, and insulin resistance are evenly induced, and which successfully reproduces the progression of a series of severe liver diseases, from hepatitis and excessive fibrogenesis in liver tissue through tissue hardening (cirrhosis) to liver cancer, and reflects the characteristics of each stage with high reliability. Accordingly, the present invention may be useful as a means for developing a therapeutic agent for chronic liver disease as well as studying the molecular and circulatory mechanisms of each stage of liver disease.
Owner:IND ACADEMIC COOP FOUND YONSEI UNIV

Application of FBXO22 in diagnosis and treatment of non-alcoholic fatty liver disease

The invention provides application of FBXO22 in diagnosis and treatment of a non-alcoholic fatty liver disease, discloses high expression of FBXO22 in the non-alcoholic fatty liver disease, and verifies that the process of the non-alcoholic fatty liver disease can be delayed, liver inflammation can be relieved and liver lipid accumulation can be slowed down by reducing the expression level of the FBXO22. The FBXO22 can be used for diagnosing and treating the non-alcoholic fatty liver disease and screening candidate drugs for the non-alcoholic fatty liver disease, and the FBXO22 can also be used for evaluating the drug effect and researching and revealing the pathogenesis of the non-alcoholic fatty liver disease. The invention has important significance for clinical research of the non-alcoholic fatty liver disease.
Owner:XUZHOU MEDICAL UNIVERSITY

Application of CAP-Gly functional peptide in preparation of medicine for treating fatty liver

PendingCN119139456AReduce lipid accumulationpromote phosphorylationPeptide/protein ingredientsDigestive systemPhosphorylationAdenosine 5 monophosphate
The invention relates to the technical field of drugs for gene therapy, in particular to application of CAP-Gly functional peptide in preparation of drugs for treating fatty liver. The invention provides application of a CAP-Gly functional peptide or a reagent for improving the expression quantity of the CAP-Gly functional peptide in preparation of a medicine for treating fatty liver. The amino acid sequence of the CAP-Gly functional peptide is shown as SEQ ID NO.23. The invention further provides a preparation method of the CAP-Gly functional peptide. The invention finds that the overexpression of the KIF13B protein or the CAP-Gly functional peptide thereof in mice can effectively reduce lipid accumulation in liver cells and increase phosphorylation of protein kinase alpha activated by adenosine monophosphate, and provides a new target and a new strategy for precise treatment of patients with fatty liver (especially metabolism-related fatty liver diseases) clinically.
Owner:PEKING UNIV +1

Double stranded oligonucleotide compositions for RNA interference and methods relating thereto

The present disclosure provides double stranded oligonucleotides, compositions, and methods relating thereto. The present disclosure encompasses the recognition that structural elements of double stranded oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and / or internucleotidic linkages) or patterns thereof, and / or stereochemistry (e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages), and / or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, Ago2 loading, thermal stability, in vivo stability, delivery to tissues and into cells, etc. The present disclosure also provides methods for treatment of diseases, e.g., hepatic diseases, central nervous system (CNS) diseases, etc., using provided double stranded oligonucleotide compositions, for example, in RNA interference.
Owner:WAVE LIFE SCI LTD

Coprococcus eutaxus strain and application thereof

PendingCN120366119ABacteriaMetabolism disorderBiotechnologyCoprococcus eutactus
The invention discloses a Coprococcus eutaxus strain and an application of the Coprococcus eutaxus strain, and relates to the technical field of probiotics. According to the present invention, the Coprococcus eutactus strain is named as Coprococcus eutactus GZSY125, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, the preservation unit is Guangdong Microbial Culture Collection Center, and the address of the preservation unit is the fifth floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangdong Province, the preservation number is CGMCC No.66029, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, and the preservation number is CGMCC No.66029. The invention provides the Coprococcus eutaxus, the Coprococcus eutaxus can be used for remarkably improving liver lipid accumulation, inflammation and fibrosis, has a certain treatment effect on the metabolism-related fatty liver disease (MAFLD), provides a new treatment thought for clinically intervening the MAFLD, and has important clinical significance on the treatment of the MAFLD.
Owner:GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)

Compositions and uses

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.
Owner:TATE & LYLE SOLUTIONS USA LLC

Application of alnulone and analogue thereof in prevention and treatment of fatty liver disease

The invention belongs to the technical field of biological medicines, and provides application of alnulone and analogues thereof in prevention and treatment of fatty liver diseases and auxiliary blood fat reduction. The invention also provides a composition for treating fatty liver diseases or assisting in reducing blood fat. The composition comprises an effective dose of alnulone and analogues thereof. The alnnulone and the analogue thereof provided by the invention have the effects of reducing blood triglyceride and liver triglyceride and reversing liver fatty degeneration in vivo, can improve liver fibrosis and inflammation symptoms of a mouse with steatohepatitis, and are good in safety, free of toxic and side effects and free of toxic and side effects. The compound can be used for preparing medicines for preventing and treating fatty liver diseases, steatohepatitis and related diseases.
Owner:SHANDONG UNIV

Application of jonquil glucoside in preparation of medicine for treating metabolism-related fatty liver disease

The invention belongs to the technical field of biological pharmacy, and provides an application of jonquil glucoside in preparation of a medicine for treating a metabolism-related fatty liver disease, and the application is that the jonquil glucoside is applied to preparation of the medicine for treating the metabolism-related fatty liver disease. The treatment effect of the jonquil glycoside on MASLD is evaluated by adopting a method for establishing a fatty liver model through induction of HFD high-fat, high-fructose and high-cholesterol feed. Results show that the jonquil glucoside can reduce the liver weight by inhibiting weight gain, reduce the content of TC and TG in serum, improve the conditions of liver inflammation and fat change, reduce the oxidative stress level of liver tissue and restore SIRT1 protein expression of the liver tissue to achieve the purpose of treating MASLD.
Owner:SHANGHAI HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Traditional Chinese medicine composition for preventing and treating metabolism-related fatty liver diseases or metabolic syndromes

The invention discloses a traditional Chinese medicine composition for preventing and treating metabolism-related fatty liver diseases or metabolic syndromes. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 5-50 parts of sweet wormwood, 3-30 parts of scutellaria baicalensis, 5-50 parts of dandelion, 4-60 parts of platycodon grandiflorum, 5-50 parts of fructus aurantii, 3-80 parts of rhizoma pinelliae preparata, 3-70 parts of fructus amomi, 10-80 parts of stir-fried Chinese yam, 5-80 parts of poria cocos and 3-100 parts of raw coix seeds. The traditional Chinese medicine composition for preventing and treating the metabolism-related fatty liver diseases or the metabolic syndromes is simple in formula, proper in compatibility and mild in medicine property, is used for preventing and treating the metabolism-related fatty liver diseases or the metabolic syndromes, is used for improving liver fatty degeneration and inflammation, blood uric acid, blood fat, blood sugar and blood pressure, assisting weight loss and the like, and is safe to use and remarkable in curative effect.
Owner:BEIJING UNIV OF CHINESE MEDICINE

17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof

PCT designated stage expiredWO2024263605A2Organic active ingredientsOrganic chemistryAlcoholic cirrhosisFibrosis
17-Beta-hydroxysteroid dehydrogenase type 13 (17β-HSD13) plays an important role in the pathogenesis and progression of Non-alcoholic fatty liver disease (NAFLD), also known as Metabolic dysfunction-associated steatotic liver disease (MASLD), and Alcohol-related liver disease (ARLD). Loss-of-function variant of 17β-HSD13 has been associated with a significantly reduced risk of NAFLD (MASLD), cirrhosis associated with nonalcoholic steatohepatitis (NASH (MASH)), alcoholic-related liver disease, alcoholic cirrhosis, hepatocellular carcinoma (HCC), hepatitis C chronic liver disease, pediatric liver disease, NASH (MASH) disease severity, ballooning degeneration, lobular inflammation, and fibrosis. The present invention relates to hydantoin compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use for treatment and prevention of above mentioned liver diseases.
Owner:BLUEJAY THERAPEUTICS INC

Traditional Chinese medicine composition for treating fatty liver diseases related to metabolic dysfunction and application of traditional Chinese medicine composition

The invention discloses a traditional Chinese medicine composition for treating fatty liver diseases related to metabolic dysfunction. The traditional Chinese medicine composition is prepared from the following raw material medicines: Qu fructus aurantii, lotus leaves, semen cassiae, gynostemma pentaphylla, rhizoma alismatis, rhodiola rosea, radix salviae miltiorrhizae, pseudo-ginseng and rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition and the traditional Chinese medicine compound preparation disclosed by the invention can improve the blood sugar and blood fat levels of fatty liver diseases related to metabolic dysfunction and improve the metabolic level, are remarkable in clinical curative effect, improve the living quality of patients, have the effects of regulating qi, soothing the liver, tonifying the spleen and removing stasis, slow down liver fibrosis by improving blood sugar and blood fat metabolism, and are quick in curative effect and low in price.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY